Former VP, Research and Development · Alaunos Therapeutics, Inc. (TCRT)

Drew Deniger

A named executive officer of Alaunos Therapeutics in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$733,352

Salary $317,757Stock awards $0Bonus $103,672

FY2022: $949,113

3rd of 4 named executive officers at Alaunos Therapeutics by FY2023 total.

4 named officers on file for Alaunos Therapeutics, FY2023

Drew Deniger’s pay file — $29

  • 2 fiscal years of pay, line by line
  • TCRT’s disclosed peer group of 1 company

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Alaunos Therapeutics’s whole pay program stands against its peers

  • Alaunos Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TCRT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 21, 2025 (DEF 14A).

Free

Get Drew Deniger’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Drew Deniger compensation by year

Alaunos Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Alaunos Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$345,572$317,757
Bonus$103,672$103,672
Stock awards$0$0
Option awards$481,229$47,888
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$18,640$264,035
Total$949,113$733,352

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Alaunos Therapeutics, Inc. DEF 14A filed May 21, 2025, accession 0001193125-25-123677, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Alaunos Therapeutics, Inc. filed document, accession 0001193125-25-123677. Every figure is read from that document and cited to the page and table it appears in. Filed May 21, 2025.

$949K
$733K
FY22
FY23
SalaryBonusOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU2,812$1,828—
Option9,375—$4.13
Option31,250—$2.82
Option285,938—$2.11
Option17,500—$4.31
Option187,500—$1.50

Per the Outstanding Equity Awards at Fiscal Year-End table in Alaunos Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Alaunos Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Kevin BoyleFormer Chief Executive Officer$1,986,946
Melinda LackeySVP, Legal & Administration$831,737
Drew Deniger · this pageFormer VP, Research and Development$733,352
Dale HogueInterim Chief Executive Officer$48,153

The full Alaunos Therapeutics compensation record

free company brief

This page is one person within Alaunos Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Alaunos Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Alaunos Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Drew Deniger's compensation dossier · One-time report. No refunds.